Brentuximab vedotin approved in Japan for frontline treatment of HL

Brentuximab vedotin has received approval by the Japanese Ministry of Health, Labour and Welfare, for the frontline treatment of CD30+ Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). 

This approval follows results from the ECHELON-1 trial. Results from the ECHELON-1 phase III study were presented during a plenary scientific session at the 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) in Atlanta, GA, on December 10th, 2017. Professor Anas Younes commented on the outcomes of the study in an interview with the Lymphoma Hub.



Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!